Correctsequence
Shanghai, CN · 2 known investors
CorrectSequence Therapeutics (正序生物) develops precision therapies based on its proprietary base editing platform, targeting genetic diseases such as thalassemia and sickle cell disease. Its pipeline includes in vitro and in vivo base editing drug candidates (e.g. CS-101 and CS-121) for patients with rare and blood disorders, with operations based in Shanghai, China.
BiotechDeep TechHealthtech
Founders & leadership
牟
牟晓盾CEO
Investors · 2
Frequently asked questions
- What does Correctsequence do?
- CorrectSequence Therapeutics (正序生物) develops precision therapies based on its proprietary base editing platform, targeting genetic diseases such as thalassemia and sickle cell disease. Its pipeline includes in vitro and in vivo base editing drug candidates (e.g. CS-101 and CS-121) for patients with rare and blood disorders, with operations based in Shanghai, China.
- Who are Correctsequence's investors?
- Correctsequence's investors include LAV, Lilly Asia Ventures.
- Where is Correctsequence headquartered?
- Correctsequence is headquartered in Shanghai, CN.